21 June 2012 – Medical Research Network (MRN), a Clinical Trial Support Organisation (CTSO) offering home trial and site nurse support as well as bespoke recruitment and retention services, has unveiled its new patient scheduling tool to manage, report and track clinical trial projects in real time.
MRN-SMART incorporates a digital pen data capture facility, ensuring all source data compiled in the patient’s home is rapidly transmitted to the clinical trial site.
When MRN’s nurses visit patients in the home they can complete their records forms as usual however now data is now also automatically stored electronically on a central network which provides automatic tracking, enhanced visibility of trial data and increased security.
Dr Graham Wylie, CEO of MRN, commented: “We always strive for efficiency and effectiveness in all that we do. We work to defined quality management systems and are continually developing our tools to truly globalise the delivery ofhomecare in clinical trials.
“With MRN-SMART we offer greater security, real-time access to trial information and create cost savings.”
MRN-SMART is part of the MRN INNOVATION suite of tools and integrates with MRN-TEC, an interactive online portal offering study-specific and GCP training for nurses within MRN projects. The suite gives MRN a unique capability to train and manage large teams across the globe. Completing the MRN-INNOVATION suite isMRN-COMPLY, a quality and compliance system ensuring high standards of careacross all global trials.
Dr Wylie added: “I’m delighted to be launching MRN-SMART; it’s going to significantly help to combat the challenges posed by operating clinical trials across multiple timelines, numerous continents and time zones.”
MRN will officially launch MRN-SMART at the DIA Annual Meeting in Philadelphia next week on booth #2745. For further information on MRN-SMART and the MRN-INNOVATION suite of tools visit www.themrn.co.uk.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.